

REMARKS

Claims 1-19 are pending. No extension of time is required because this reply is being made within one month from the mailing date of the Notification.

Substitute paper and computer readable forms of the Sequence Listing are being submitted herewith in response to the requirement to comply with the Sequence Rules 37 CFR § 1.821 et seq. The attached substitute paper and computer readable forms of the Sequence Listing do not add new matter, and their contents are the same. Another amino acid sequence has been added. Prompt notice of any defects in the Sequence Listing is earnestly solicited and additional time is requested to comply.


No new matter is added by the amendments. In particular, the priority claims has been corrected and a sequence identifier has been added.

Applicants earnestly solicit an early examination on the merits. The Examiner is invited to contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:



Gary R. Vanigawa
Reg. No. 43,180

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

APPENDIX

MARKED-UP VERSION TO SHOW CHANGES

IN THE SPECIFICATION

The specification is amended as follows.

Page 1, first paragraph starting on line 1:

This is a national stage application of PCT/GB99/01434, filed on May 7, 1999 under 35 U.S.C. 371, [now abandoned] designating the United States and published in English.

Page 6, third paragraph starting on line 19:

The framework of the variable region of the antibody light chain is typically substantially homologous to the variable domain framework of the protein HSIKGVII (SEQ ID NO:54, EMBL data base: Klobeck, H.G., EMBL data library submitted 7th April, 1986). There is a frameshift in this sequence at position 452. To rectify the reading frame, a deletion of base 452(T) is made.

IN THE SEQUENCE LISTING

Substitute paper and computer readable copies of the Sequence Listing are attached.